627 results on '"de Sauvage, Frederic"'
Search Results
2. Adrenergic nerves regulate intestinal regeneration through IL-22 signaling from type 3 innate lymphoid cells
3. Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation
4. Antibody targeting of E3 ubiquitin ligases for receptor degradation
5. Lgr5+ telocytes are a signaling source at the intestinal villus tip.
6. Obligate role for Rock1 and Rock2 in adult stem cell viability and function
7. Disruption of stem cell niche–confined R-spondin 3 expression leads to impaired hematopoiesis
8. Atoh1+ secretory progenitors possess renewal capacity independent of Lgr5+ cells during colonic regeneration
9. Parasitic helminths induce fetal-like reversion in the intestinal stem cell niche
10. Gremlin 1+ fibroblastic niche maintains dendritic cell homeostasis in lymphoid tissues
11. The great escape: tumour cell plasticity in resistance to targeted therapy
12. Opposing Activities of Notch and Wnt Signaling Regulate Intestinal Stem Cells and Gut Homeostasis
13. Modeling Colorectal Cancer Progression Through Orthotopic Implantation of Organoids
14. Lgr5-Expressing Cells Are Sufficient and Necessary for Postnatal Mammary Gland Organogenesis
15. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition
16. Activity-Dependent Internalization of Smoothened Mediated by β-Arrestin 2 and GRK2
17. Abstract A039: RAS signaling strength determines phenotypic response in the colon
18. IL-27 Regulates IL-12 Responsiveness of naïve CD4 + T Cells through Stat1-Dependent and -Independent Mechanisms
19. Permissive Role of Thrombopoietin and Granulocyte Colony-Stimulating Factor Receptors in Hematopoietic Cell Fate Decisions in vivo
20. Characterization of Two Patched Receptors for the Vertebrate Hedgehog Protein Family
21. A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells
22. Data from Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
23. Supplementary Figure from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
24. Supplementary Data from Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
25. Supplementary Data Figures from A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer
26. Supplementary Data Tables from A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer
27. Supplementary Figure 1 from Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation
28. Supplementary Data from Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
29. Supplementary Table 3 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
30. Supplementary Figure 3 from PTEN Loss Mitigates the Response of Medulloblastoma to Hedgehog Pathway Inhibition
31. Data from PTEN Loss Mitigates the Response of Medulloblastoma to Hedgehog Pathway Inhibition
32. Supplementary Figure Legend from PTEN Loss Mitigates the Response of Medulloblastoma to Hedgehog Pathway Inhibition
33. Data from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
34. Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
35. Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
36. Data from Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection
37. Supplementary Table 4 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
38. Data from Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers
39. Supplementary Figure 5 from PTEN Loss Mitigates the Response of Medulloblastoma to Hedgehog Pathway Inhibition
40. Supplementary Methods, Figure Legends 1-6 from Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
41. Supplementary Figure 1 from Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection
42. Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
43. Supplementary Table 1 from Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
44. Supplementary Figure 1 from PTEN Loss Mitigates the Response of Medulloblastoma to Hedgehog Pathway Inhibition
45. Supplementary Table 6 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes
46. Supplementary Figures 1-6 from Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
47. Supplementary Table 1 from Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection
48. Data from Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
49. Supplementary Legends from Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers
50. Supplementary Figure 4 from PTEN Loss Mitigates the Response of Medulloblastoma to Hedgehog Pathway Inhibition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.